CoChat

Comparative study of esketamine and racemic ketamine in treatment-resistant depression: Protocol for a non-inferiority clinical trial

Open access
Correia-Melo, Fernanda S., Leal, Gustavo C., Carvalho, Michelle S., Jesus-Nunes, Ana Paula, Ferreira, Carolina B.N., Vieira, Flávia, Magnavita, Guilherme, Vale, Lucas A.S., Mello, Rodrigo P., Nakahira, Carolina, Argolo, Felipe C., Cardoso, Tanise, Souza, Cezar D.S., Fontes, Ana Teresa C., Ferreira, Marcelo B., Araújo-de-Freitas, Lucas, Tuena, Marco A., Echegaray, Mariana V.F., Cavalcanti, Diogo E., Lucchese, Ana C., Bandeira, Igor D., Telles, Manuela, Lima, Cássio S., Sampaio, Aline S., Silva, Samantha S., Marback, Roberta F., Del-Porto, José A., Abreu, José Neander, Sarin, Luciana M., Paixão, Camilla S., Carvalho, Lucas P., Machado, Paulo R.L., Turecki, Gustavo, Lacerda, Acioly L.T., Quarantini, Lucas C. · 2018 · Medicine
Cited by 61

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Abstract

INTRODUCTION: The use of ketamine as an option in the treatment of depressive disorder is growing rapidly, supported by numerous clinical trials attesting its efficacy and safety. Esketamine, the S (+) enantiomer of ketamine, is the most widely used form in the anesthetic environment in some countries, and new studies have shown that it may also be effective in depression and with better tolerability. However, no study so far has directly compared esketamine with racemic ketamine. Here we propose a protocol of a clinical trial to evaluate esketamine as a noninferior medication when compared to ketamine in the treatment of patients with treatment-resistant depression. METHODS/DESIGN: This study protocol is for a randomized, controlled, double-blind noninferiority clinical trial. Subjects will be 18 years or older, with major depression characterized as treatment-resistant. Participants will receive a single infusion of either esketamine (0.25 mg/kg) or ketamine (0.5 mg/kg) over 40 minutes. The primary outcome will be the difference in remission rates between the 2 treatment arms at 24 and 72 hours after drug infusion. Secondary outcomes will include other timepoints, measurements of cognition, dissociation, and blood biomarkers. DISCUSSION: A head-to-head study is the best way to evaluate whether the esketamine is in fact comparable to the racemic ketamine in terms of both efficacy and safety, and, if positive, it would be an initial step to increase the access to that type of treatment worldwide. ETHICS AND DISSEMINATION: The study was approved by the local Institutional Review Board (University Hospital Professor Edgard Santos-Federal University of Bahia-Number: 46657415.0.0000.0049). Subjects will only participate after voluntarily agreeing and signing the Informed Consent Form. The study findings will be published in peer-reviewed journals and presented at national and international conferences. TRIAL REGISTRATION: This trial has been registered in the Japan Primary Registries Network (JPRN): UMIN000032355, which is affiliated with the World Health Organization.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/md.0000000000012414

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 20 references

Cited by

See all 61

Metadata

Authors
Correia-Melo, F. S., Leal, G. C., Carvalho, M. S., Jesus-Nunes, A. P., Ferreira, C. B. N., Vieira, F., Magnavita, G., Vale, L. A. S., Mello, R. P., Nakahira, C., Argolo, F. C., Cardoso, T., Souza, C. D. S., Fontes, A. T. C., Ferreira, M. B., Araújo-de-Freitas, L., Tuena, M. A., Echegaray, M. V. F., Cavalcanti, D. E., Lucchese, A. C., Bandeira, I. D., Telles, M., Lima, C. S., Sampaio, A. S., Silva, S. S., Marback, R. F., Del-Porto, J. A., Abreu, J. N., Sarin, L. M., Paixão, C. S., Carvalho, L. P., Machado, P. R. L., Turecki, G., Lacerda, A. L. T., & Quarantini, L. C.
Venue
Medicine
Published
2018-09
Volume
97
Issue
38
Pages
e12414
ISSN
0025-7974 (ISSN-L)
OpenAlex
W2895589451
Cited by
61
References
20
FWCI
3.79
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Comparative study of esketamine and racemic ketamine in treatment-resistant depression: Protocol for a non-inferiority clinical trial. https://app.cochat.ai/papers/10.1097/md.0000000000012414
The paper
Correia-Melo, F. S., Leal, G. C., Carvalho, M. S., Jesus-Nunes, A. P., Ferreira, C. B. N., Vieira, F., Magnavita, G., Vale, L. A. S., Mello, R. P., Nakahira, C., Argolo, F. C., Cardoso, T., Souza, C. D. S., Fontes, A. T. C., Ferreira, M. B., Araújo-de-Freitas, L., Tuena, M. A., Echegaray, M. V. F., Cavalcanti, D. E., . . . Quarantini, L. C. (2018). Comparative study of esketamine and racemic ketamine in treatment-resistant depression: Protocol for a non-inferiority clinical trial. Medicine. https://doi.org/10.1097/md.0000000000012414

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.